Combined p14ARF and antisense EGFR potentiate the efficacy of adenovirus-mediated gene therapy in laryngeal squamous cell carcinoma (LSCC)

DNA and Cell Biology

Volumn 26, Issue 2, 2007, Pages 71-79

  Xian, Junming ^a   Lin, Yinghe ^b   Liu, Yafeng ^a   Gong, Ping ^c   Liu, Shixi ^a  

^a SICHUAN UNIVERSITY   (China)

^b Hospital of Stomatology   (China)

^c SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR; ADENOVIRUS VECTOR; COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; GENE PRODUCT; PHOSPHATE BUFFERED SALINE; PROTEIN P14ARF;

ANTISENSE THERAPY; ARTICLE; CANCER GENE THERAPY; CARCINOGENESIS; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; EGFR GENE; FLOW CYTOMETRY; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HEP 2 CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LARYNX CARCINOMA; NONHUMAN; P14 ARF GENE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTO ONCOGENE; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; WESTERN BLOTTING; ADENOVIRUS; BIOSYNTHESIS; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; GENE THERAPY; GENE VECTOR; GENETICS; LARYNX TUMOR; PATHOLOGY; TUMOR CELL LINE;

ADENOVIRIDAE;

ADENOVIRIDAE; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DNA, ANTISENSE; GENE THERAPY; GENETIC VECTORS; HUMANS; LARYNGEAL NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 33847623770     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/dna.2006.0533     Document Type: Article

References (25)

1. ALMADORI, G., CADONI, G., GALLI, J., et al. (1999). Growth factor receptor expression in primary laryngeal cancer: An independent prognostic factor of neck node relapse. Int. J. Cancer 84, 188-191.
2. ANDRIQUE, L., AYRAULT, O., LARSEN, C.J., SEITE, P. (2005). In vitro and in vivo analysis of the interaction between 5.8S rRNA and ARF protein reveal a new difference between murine p19ARF and human p14ARF. Oncogene 24, 2580-2584.
3. ARF links the tumour suppressors RB and p53. Nature 395, 124-125.
4. BLACKWELL, J.L., MILLER, C.R., DOUGLAS, J.T., et al. (1999). Retargeting to EGFR enhances adenovirus infection efficiency of squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 125, 856-863.
5. CHUN, K.-H., KOSMEDER, J.W., II, et al. (2003). Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. J. Natl. Cancer Inst. 95, 91-302.
6. DANIEL, P.T., STURM, I., RITSCHEL, S., FRIEDRICH, K., et al. (1999). Detection of genomic DNA fragmentation during apoptosis (DNA ladder) and the simultaneous isolation of RNA from low cell numbers. Anal. Biochem. 266, 110-115.
7. FALLAUX, F.J., KRANENBURG, O., CRAMER, S.J., et al. (1996). Characterization of 911: A new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum. Gene Ther. 7, 215-222.
8. GRUTTGEN, A., REICHENZELLER, M., Junger, M., et al. (2001). Detailed gene expression analysis but not microsatellite marker analysis of 9p21 reveals differential defects in the INK4a gene locus in the majority of head and neck cancers. J. Pathol. 194, 311-317.
9. HE, T.C., ZHOU, S., VOGELSTEIN, B., et al. (1998). A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. USA 95, 2509-2514.
10. KAMB, A., GRUIS, N.A., WEAVER-FELDHAUS, J., et al. (1994). A cell cycle regulator potentially involved in genesis of many tumor types. Science 264, 436-440.
11. LEACH, F.S., TOKINO, T., MELTZER, P., BURRELL, M., et al. (1993). p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res. 53, 2231-2234.
12. LO, H.W., HSU, S.C., and HUNG, M.C. (2005). EGFR signaling pathway in breast cancers: From traditional signal transduction to direct nuclear translocalization. Breast Cancer Res. Treat. 28, 1-8.
13. MATTHEWS, D.A., CUMMINGS, D., EVELEGH, C., GRAHAM, F.L., and PREVEC, L. (1999). Development and use of a 293 cell line expressing lac repressor for the rescue of recombinant adenoviruses expressing high levels of rabies virus glycoprotein. J. Gen. Virol. 80, 345-353.
14. MOSMANN, T. (1983). Rapid colorimetric assay for cellular growth andsurvival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55-63.
15. MYERS, J.N., HOLSINGER, F.C., BEKELE, N., et al (2002). Target molecular therapy for oral cancer with epidermal growth factor receptor blockade. Arch. Otolaryngol. Head Neck Surg. 128, 875-879.
16. NADAL, A., and CARDESA, A. (2003). Molecular biology of laryngeal squamous cell carcinoma. Virchows Arch. 442, 1-7.
17. NOBORI, T., MIURA, K., WU, D.J., et al. (1994). Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368, 753-756.
18. PRASHER, D.C., ECKENRODE, V.K., WARD, W.W., et al. (1992). Primary structure of the Aequorea victoria green-fluorescent protein. Gene 111, 229-233.
19. RAITIOLA, H., PUKANDER, J., LAIPPALA, P. (1999). Glottic and supraglottic laryngeal carcinoma: differences in epidemiology, clinical characteristics and prognosis. Acta Otolaryngol. 119, 847-851.
20. RIZOS, H., DARMANIAN, A.P., MANN, G.J., et al. (2000). Two arginine rich domains in the p14ARF tumour suppressor mediate nucleolar localization. Oncogene 19, 2978-2985.
21. ARF nuclear overexpression in aggressive B-cell lymphomas is a sensor of malfunction of the common tumor suppressor pathways. Blood 99, 1411-1418.
22. 1-phase progression. Genes Dev. 13, 1501-1512.
23. SMITH, B.D., SMITH, G.L., CARTER, D., DIGIOVANNA, M.P., et al. (2001). Molecular marker expression in oral and oropharyngeal squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 127, 780-785.
24. STOTT, F.J., BATES, S., JAMES, M.C., et al. (1998). The alternative product from the human CDKN2A locus, p14 (ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17, 5001-5014.
25. WEINBERGER, P.M., YU, Z., KOWALSKI, D., JOE, J., et al. (2005). Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies. Arch. Otolaryngol. Head Neck Surg. 131, 707-711.